BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27108527)

  • 1. Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma.
    Gao J; Zhao S; Halstensen TS
    Oncol Rep; 2016 Jun; 35(6):3265-74. PubMed ID: 27108527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
    Stanam A; Gibson-Corley KN; Love-Homan L; Ihejirika N; Simons AL
    Oncotarget; 2016 Nov; 7(46):76087-76100. PubMed ID: 27738319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
    Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
    Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
    Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
    PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment.
    Wang YF; Chang CJ; Chiu JH; Lin CP; Li WY; Chang SY; Chu PY; Tai SK; Chen YJ
    Oncotarget; 2014 Sep; 5(17):7392-405. PubMed ID: 25277180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.
    Köberle B; Ditz C; Kausch I; Wollenberg B; Ferris RL; Albers AE
    Int J Oncol; 2010 May; 36(5):1277-84. PubMed ID: 20372803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
    Nör C; Zhang Z; Warner KA; Bernardi L; Visioli F; Helman JI; Roesler R; Nör JE
    Neoplasia; 2014 Feb; 16(2):137-46. PubMed ID: 24709421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
    Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
    O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR
    PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
    Nishimura K; Tsuchiya Y; Okamoto H; Ijichi K; Gosho M; Fukayama M; Yoshikawa K; Ueda H; Bradford CR; Carey TE; Ogawa T
    Br J Cancer; 2014 Aug; 111(4):799-806. PubMed ID: 25032734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.
    Jiffar T; Yilmaz T; Lee J; Hanna E; El-Naggar A; Yu D; Myers JN; Kupferman ME
    Oncogene; 2011 Jul; 30(28):3163-73. PubMed ID: 21383688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma.
    Gu F; Ma Y; Zhang Z; Zhao J; Kobayashi H; Zhang L; Fu L
    Oncol Rep; 2010 Mar; 23(3):671-6. PubMed ID: 20127005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
    Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma.
    Chen SF; Nieh S; Jao SW; Wu MZ; Liu CL; Chang YC; Lin YS
    J Pathol; 2013 Oct; 231(2):180-9. PubMed ID: 23775566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.